1. Home
  2. KOS vs ADCT Comparison

KOS vs ADCT Comparison

Compare KOS & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kosmos Energy Ltd. (DE)

KOS

Kosmos Energy Ltd. (DE)

N/A

Current Price

$2.42

Market Cap

1.1B

Sector

Energy

ML Signal

N/A

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

N/A

Current Price

$4.81

Market Cap

484.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KOS
ADCT
Founded
2003
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
484.4M
IPO Year
2011
2019

Fundamental Metrics

Financial Performance
Metric
KOS
ADCT
Price
$2.42
$4.81
Analyst Decision
Hold
Strong Buy
Analyst Count
6
5
Target Price
$1.76
$7.50
AVG Volume (30 Days)
20.8M
801.2K
Earning Date
01-01-0001
03-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
44.90
EPS
N/A
N/A
Revenue
$1,288,352,000.00
$70,837,000.00
Revenue This Year
$16.95
$14.96
Revenue Next Year
$7.76
$1.06
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1.84
52 Week Low
$0.84
$1.05
52 Week High
$2.70
$4.80

Technical Indicators

Market Signals
Indicator
KOS
ADCT
Relative Strength Index (RSI) 63.59 68.24
Support Level $1.52 $3.79
Resistance Level $2.43 N/A
Average True Range (ATR) 0.23 0.27
MACD 0.01 0.02
Stochastic Oscillator 62.93 83.66

Price Performance

Historical Comparison
KOS
ADCT

About KOS Kosmos Energy Ltd. (DE)

Kosmos Energy Ltd is a deepwater exploration and production company focused on meeting the world's growing demand for energy. It has diversified oil and gas production from assets offshore Ghana, Equatorial Guinea, Mauritania, Senegal and the Gulf of America. The Company had operations in four geographic reporting segments: Ghana, Equatorial Guinea, Mauritania/Senegal and the Gulf of America. The majority of revenue is derived from the Ghana segment.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: